Dr. Martha L. Louzada earned her medical degree and completed residency program in Brazil, her home country. In 2006, she moved to Canada to pursue a master's degree in Epidemiology and a postdoctoral fellowship in thrombosis at the University of Ottawa. In 2010, she relocated to London, Ontario, where she currently holds an appointment as Associate Professor of Medicine at Western University and London Health Sciences Centre (LHSC). Since 2016, she has served as Plasma Cell Dyscrasias Program Chair at LHSC, where she leads a multidisciplinary team of physicians, nurses, and fellows. In 2022, she was appointed Medical Director of the LHSC Hematology Research Unit where she oversees the productivity and regulatory aspects of several clinical trials in both malignant and benign hematology. She is actively involved in several research committees, such as the Department of Medicine and the Quality Improvement Research Committees at LHSC. From 2019 to 2024, she served on the steering committee of the Canadian Myeloma Research Group (CMRG) database, and she continues to collaborate with CMRG and Myeloma Canada in research endeavors, and patients’ education programs. She has collaborated in over 70 publications in peer-reviewed journals, including four clinical guidelines focused on best practices in multiple myeloma in Canada. Additionally, she actively participates in the development of medical policies and drug approvals for myeloma at national and provincial levels.